Generex Provides Stock Dividend Updates and Guidan
Post# of 36537
(Total Views: 241)
Posted On: 02/06/2020 11:51:31 AM
Generex Provides Stock Dividend Updates and Guidance
Awaiting completion of FINRA approval process
Dividends remain the same
Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares
MIRAMAR, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced an update on the pending 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology. Generex originally submitted the dividend request for a corporate action to FINRA and paid the applicable fees in November 2019. Since then, the company has responded to FINRA’s requests for further information many times, and we continue in our efforts to work diligently and cooperatively with FINRA to process the dividend. Please note that the company has no control of the FINRA approval process, which is out of Generex’ hands as to timing of any decisions.
Joe Moscato, President & CEO of Generex, said, “We regret the delay in processing the dividend and remain fully committed to paying this valuable dividend to our shareholders. I would like to thank all of you for your patience in this process. We realize this delay has eroded share value, however, based on the exhaustive review by FINRA, we believe that their approval will be given soon, at which time we will certainly inform shareholders immediately. Generex would like to thank our shareholders for standing behind us, as we continue to work in your interests with a commitment to paying these dividends as soon as possible.”
Read More: https://investorshangout.com/recentnews/GNBT#ixzz6DC3eWBIS
Awaiting completion of FINRA approval process
Dividends remain the same
Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares
MIRAMAR, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced an update on the pending 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology. Generex originally submitted the dividend request for a corporate action to FINRA and paid the applicable fees in November 2019. Since then, the company has responded to FINRA’s requests for further information many times, and we continue in our efforts to work diligently and cooperatively with FINRA to process the dividend. Please note that the company has no control of the FINRA approval process, which is out of Generex’ hands as to timing of any decisions.
Joe Moscato, President & CEO of Generex, said, “We regret the delay in processing the dividend and remain fully committed to paying this valuable dividend to our shareholders. I would like to thank all of you for your patience in this process. We realize this delay has eroded share value, however, based on the exhaustive review by FINRA, we believe that their approval will be given soon, at which time we will certainly inform shareholders immediately. Generex would like to thank our shareholders for standing behind us, as we continue to work in your interests with a commitment to paying these dividends as soon as possible.”
Read More: https://investorshangout.com/recentnews/GNBT#ixzz6DC3eWBIS
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼